


3-4-05

1646
JFW



Express Mail Label No.: ED 572755954 US

Date of Deposit: March 2, 2005

Docket No. Cura 85 CIP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Prayaga et al
SERIAL NUMBER: 09/973,424 EXAMINER: Janet L. Andres
FILING DATE: October 9, 2001 ART UNIT: 1646
FOR: POLYPEPTIDES AND POLYNUCLEOTIDES HOMOLOGOUS TO THYMOSIN, EPHRIN
A RECEPTORS, AND FIBROMODULIN

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Response to Office Action mailed December 8, 2004
- 2. Return Postcard

The Commissioner is hereby authorized to charge payment of any additional fees required in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No.502648, Reference No.Cura-85 CIP2

Respectfully submitted,


A handwritten signature in black ink, appearing to read "George Yahwak", written over a horizontal line.

George Yahwak, Reg. No. 26,824
CuraGen Corporation
555 Long Wharf Drive
New Haven, CT 06511
Tel: (203) 974-6303

Dated: March 2, 2005

Express Mail Label No.: ED 572755954 US
Date of Deposit: March 2, 2005

Attorney Docket No. 15966-585CIP2 (CURA85CIP2)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Prayaga et al
SERIAL NUMBER: 09/973,424 EXAMINER: Janet L. Andres
FILING DATE: October 9, 2001 ART UNIT: 1646
FOR: POLYPEPTIDES AND POLYNUCLEOTIDES HOMOLOGOUS TO THYMOSIN, EPHRIN
A RECEPTORS, AND FIBROMODULIN

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.111

This paper is in response to the December 8, 2004 Office Action in connection with the above-referenced application. Applicants believe that no fees are due in connection with this response as it is being submitted on March 2, 2005. If any fees are required, the Commissioner is hereby authorized to charge any fees that may be due, or credit any overpayment of same to Deposit Account No. 502648 (CURA 85CIP2).

Amendments are shown beginning on page 2 of this paper.

Remarks are shown beginning on page 3 of this paper.